MedPath

CLINUVEL, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:2
Completed:0

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:1

Drug Approvals

1

FDA:1

Drug Approvals

SCENESSE

Approval Date
Oct 16, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (33.3%)
Phase 2
1 (33.3%)
Phase 3
1 (33.3%)

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Phase 3
Active, not recruiting
Conditions
Vitiligo
Interventions
First Posted Date
2023-10-31
Last Posted Date
2025-07-08
Lead Sponsor
Clinuvel, Inc.
Target Recruit Count
200
Registration Number
NCT06109649
Locations
🇬🇧

CLINUVEL site, Manchester, United Kingdom

🇺🇸

CLINUVEL Site, Cedar Park, Texas, United States

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

Phase 2
Recruiting
Conditions
Vitiligo
Interventions
First Posted Date
2022-01-27
Last Posted Date
2023-02-09
Lead Sponsor
Clinuvel, Inc.
Target Recruit Count
6
Registration Number
NCT05210582
Locations
🇺🇸

CLINUVEL Investigational site, Detroit, Michigan, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.